OPENCELL TECHNOLOGIES, INC.
POROS platform: acoustic cell porator for macromolecule delivery (DNA, RNA, protein) into cells for CAR-T manufacturing
- Sector
- Biotech
- Headquarters
- Saint Louis, MO
- Total capital
- $3.9M
- Federal grants
- $3.9M
- 5 awards · 2015–2022
- Rank in peer group#7 of 18
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 7 pending · first 2017
- Rank in peer group#4 of 18
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Establishing the POROS Intracellular Delivery System as a Platform for Cellular Therapeutics$1.2M
- Federal grantHealth and Human S · Phase II · Establishing the POROS Intracellular Delivery System as a Platform for Cellular Therapeutics$1.8M
- Federal grantHealth and Human S · Phase I · Developing a Platform for Multiplexed Large Payload Delivery$299K
- Federal grantHealth and Human S · Phase I · Establishing the POROS Intracellular Delivery System as a Platform for Cellular Therapeutics$247K
- Federal grantHealth and Human S · Phase II · MIST System for Simultaneous Parallel Intracellular Delivery & Transfection$420K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 18 peers
Line = medianBiotech · Device
- Federal grants#7 · top 39%
- Granted patents#4 · top 22%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 2 granted of 9- PendingSystems And Methods For Mitigating Particle Aggregation Caused By Standing Wave And Transient Acoustophoretic EffectsUSPTOApplication 19290579
- GrantedSystems And Methods For Mitigating Particle Aggregation Caused By Standing Wave And Transient Acoustophoretic EffectsUSPTOUS 12,397,274
- PendingIntracellular Delivery And Transfection Methods And DevicesUSPTOApplication 16027582
Show all 9 patent records
- Systems And Methods For Mitigating Particle Aggregation Caused By Standing Wave And Transient Acoustophoretic EffectsNov 27, 2025 · Application 19290579Pending
- Systems And Methods For Mitigating Particle Aggregation Caused By Standing Wave And Transient Acoustophoretic EffectsAug 26, 2025 · US 12,397,274Granted
- Intracellular Delivery And Transfection Methods And DevicesFeb 21, 2019 · Application 16027582Pending
- Intracellular Delivery And Transfection Methods And DevicesOct 12, 2017 · Application 15629162Pending
- Intracellular Delivery And Transfection Methods And DevicesAug 8, 2017 · US 9,725,709Granted
- Cell Transfection Methods and DevicesApplication 61777980Pending
- Devices, Systems, And Methods Of Using The Devices And SystemsApplication PCTUS2024042678Pending
- Devices And Methods Of UseApplication 63519997Pending
- Systems And Methods For Mitigating Particle Aggregation Caused By Standing Wave And Transient Acoustophoretic EffectsApplication 62783771Pending
Related companies, and why
- BridgeBio Oncology TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Beam TherapeuticsSimilar federal contract value in Biotech · null in contracts
- SPINOGENIX, INC.Similar federal contract value in Biotech · null in contracts
- PAMDECA, LLCSimilar federal contract value in Biotech · null in contracts
- ALLYX BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- FIBROTHERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .